


**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

021825Orig1s000

**RISK ASSESSMENT and RISK MITIGATION
REVIEW(S)**



**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology**

Date: October 21, 2009

To: Rafel (Dwaine) Rieves, MD, Director
Division of Medical Imaging and Hematological Products
(DMIHP)

Thru: Claudia Karwoski, Pharm.D., Director
Division of Risk Management (DRISK)
Office of Surveillance and Epidemiology (OSE)

From: OSE DRISK REMS Review Team:
Mary Dempsey, Risk Management Program Coordinator,
DRISK
Suzanne Berkman Robottom, Pharm.D, Risk Analyst Team
Leader, DRISK
Joyce Weaver, Pharm.D., Senior Drug Risk Management
Analyst, DRISK, Scientific Lead

Subject: Review of Risk Evaluation and Mitigation Strategy (REMS)

Drug Name(s): Ferriprox (deferiprone)

Submission Number: 0024

Application Type/Number: NDA 21-825

Applicant/sponsor: Apopharma

OSE RCM #: 2009-354

We acknowledge the Sponsor's July 9, 2009 proposed Risk Evaluation and Mitigation Strategy (REMS) for Ferriprox (deferiprone). Due to deficiencies in the Ferriprox application, the Division of Medical Imaging and Hematological Products (DMIHP) plans to issue a Complete Response (CR) letter for this review cycle.

At this time, we will defer comment on the Sponsor's proposed REMS. A final review on the appropriate risk management strategy for deferiprone will be provided after the Sponsor responds to the deficiencies in the CR letter and the risk-benefit profile can be re-evaluated. We note that a tentative decision was made within the Agency regarding the risk mitigation strategy necessary to mitigate the risk of deferiprone-induced agranulocytosis. The Sponsor was notified in a telephone conference on August 12, 2009 that a REMS with Elements to Assure Safe Use (ETASU) to ensure monitoring of blood

counts would likely be needed. On October 14, 2009, the Sponsor submitted a proposed REMS incorporating this advice. Because this REMS proposal was submitted so close to the November 30 goal date for the application, we will not review the submission in this cycle. We suggest that the CR letter include the following paragraph after the description of the deficiencies in the application.

“Depending on the outcome of these analyses, FDA may require the submission of a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of the drug outweigh its risks. In your response to this letter, you may wish to resubmit the REMS submitted October 14, 2009.”

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE P WEAVER
10/22/2009

CLAUDIA B KARWOSKI
10/22/2009
concur